Heparin and Factor VIII

Abstract

New approaches and techniques for improving source material collection and fac Jr '111 production at Blood Bank level have been reported recently. Heparin has shown to be of great importance in increasing both yield and stability of factor VIII in the purification and concentration process. Work has been done t o develop on a routine scale a heparin double cold-precipitation technique for the production of freeze-dried high yield purified factor VIII concentrate. As a spin-off of the method red cell concentrate (RCC) and cryosupernatant plasma (SDP), both containing small amounts of heparin besides the standard CPDA-1 anticoagulant, are recovered for clinical use. Results of the tests done: RCCin wino: Normal Adenosin Tri-Phosphate (ATP), 2 3 Di-Phospho-Glycerate (DPG) and shelf-life, Heparin 0.7 IU/ml (20.3). -in wiwo: Normal half slCr-survival, no side effects. SDPin witro: Protein and chemical analysis normal, shelf-life normal, Heparin 3.5 IU/ml (5 0.7). in wivo: No side-effects, mild effect on activated Partial Thromboplastin Time (aPTT) 5 minutes post transfusion. Factor VIII concentratein wirro: Yield 56.2 (+ 8.2) percent, purity 0.8 (50.15) FVI1I:C IU/mg protein, potency 25.2 (+3.2), FVII1:C IU/ml Heparin 6.2 (?.0.7) IU/ml. -in wivo: Normal recoveries and half-lifes after injection of 15-20 IU/kg in 4 severe hemophilia A patients.This heparin small pool high yield principle is expected to have great impact on availability, access t o and safety of adequate treatment in hemophilia in the future.

The use of blood components in surgical transfusion therapy

“…It leaves the concentration of Ca 2+ intact, which increases the stability of the Factor VIII complex at +4~ [1]. The use of heparin as a primary anticoagulant has been advocated in recent years [2] with the main aim of improving the yield of Factor VIII. After collection in heparin, the red cells must be transferred into a citrate medium for further liquid storage.…”